Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Praxis Precision Medicines, Inc. - Common Stock
(NQ:
PRAX
)
278.19
-56.97 (-17.00%)
Streaming Delayed Price
Updated: 1:22 PM EDT, Jun 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Praxis Precision Medicines, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Why Praxis Precision Medicines Stock Is Trading Higher Tuesday
↗
March 26, 2024
Praxis Precision Medicines updates Phase 2a study on PRAX-628 in epilepsy patients with photo paroxysmal response, indicating positive response and safety profile, advancing plans for focal epilepsy...
Via
Benzinga
Tesla, Krispy Kreme, McCormick And Other Big Stocks Moving Higher On Tuesday
↗
March 26, 2024
U.S. stocks were higher, with the Dow Jones index gaining around 50 points on Tuesday.
Via
Benzinga
Topics
Stocks
Praxis, A Top 1% Stock, Soars To Year-High After Epilepsy Treatment Scores Big
↗
March 26, 2024
The company said 100% of patients who received the high dose responded to its drug.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
March 26, 2024
Via
Benzinga
Recap: Praxis Precision Medicine Q4 Earnings
↗
March 05, 2024
Via
Benzinga
Where Praxis Precision Medicine Stands With Analysts
↗
October 03, 2023
Via
Benzinga
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
March 26, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Host PRAX-628 Program Update
March 25, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
PRAX Stock Earnings: Praxis Precision Medicine Beats EPS, Beats Revenue for Q4 2023
↗
March 05, 2024
PRAX stock results show that Praxis Precision Medicine beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
March 05, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference
March 01, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Jim Cramer: This Healthcare Stock Is 'Too Risky,' But Shares Jumped 64% Over Past Month
↗
January 25, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is "too risky."
Via
Benzinga
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
↗
January 13, 2024
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...
Via
Talk Markets
Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering
January 11, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
January 10, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
January 08, 2024
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on...
Via
Benzinga
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
January 08, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China
January 05, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings
November 28, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
November 16, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium
November 02, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
October 02, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023
September 27, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023
↗
September 19, 2023
Via
Benzinga
Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 07, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy Congress
August 31, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress
August 28, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
